Federal Register / Vol. 73, No. 164 / Friday, August 22, 2008 / Notices 49691 

gliomas, lung, breast or prostate cancers 

but not in serum from controls. 

The correlation between cancer and 

BORIS expression indicates that 

detection of aberrantly expressed BORIS 

and/or anti-BORIS antibodies could 

serve as a method of screening or 

diagnosing cancer. In patients already 

known to have cancer, expression of 

BORIS could be monitored to measure 

a patient’s response to a particular 

therapeutic regimen. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR Part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establish that the grant of 

the license would not be consistent with 

the requirements of 35 U.S.C. 209 and 

37 CFR Part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: August 14, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–19454 Filed 8–21–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: The Development of 

Inmunotoxins as Therapeutics for 

Focal Muscle Spasms 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209(c)(l) and 37 CFR part 

404.7(a)(l)(i), that the National Institutes 

of Health, Department of Health and 

Human Services, is contemplating the 

grant of an exclusive patent license to 

practice the invention embodied in 

issued U.S. Patent 6,780,413 entitled 

‘‘Immunotoxin (MAB–Ricin) for the 

Treatment of Focal Movement 

Disorders’’ [HHS Ref. E–132–1996/0–

US–04] to Aphrodite Therapeutics, Inc., 

which has offices in Vancouver, Canada. 

This patent has been assigned to the 

Government of the United States of 

America. There are no foreign patents or 

patent applications associated with this 

technology. There are no other U.S. 

Patents or Patent Applications 

associated with this technology. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use maybe limited to the 

development and sale of antibody 

conjugated toxins targeting the nicotinic 

acetylcholine receptors for therapeutic 

treatment of focal muscle spasms, as 

claimed in the Licensed Patent Rights. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

October 21, 2008 will be considered. 

ADDRESSES: Requests for copy of the 

patent, inquiries, comments, and other 

materials relating to the contemplated 

exclusive license should be directed to: 

Betty B. Tong, PhD, Technology 

Licensing Specialist, Office of 

Technology Transfer, National Institutes 

of Health, 6011 Executive Boulevard, 

Suite 325, Rockville, MD 20852–3804; 

Telephone: (301) 594–6565; Facsimile: 

(301) 402–0220; E-mail: 

tongb@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

invention describes immunotoxins and 

methods of using the immunotoxins for 

the treatment of focal muscle spasms. A 

specific immunotoxin covered by this 

technology is MAB–Ricin. The 

immunotoxins are targeted via an 

antibody that is specific to acetylcholine 

receptors present in large numbers on 

the muscle side of the neuromuscular 

junction, allowing the specific 

destruction of muscle cells. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: August 14, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–19463 Filed 8–21–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

In compliance with Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collections of information, the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

will publish periodic summaries of 

proposed projects. To request more 

information on the proposed projects or 

to obtain a copy of the information 

collection plans, call the SAMHSA 

Reports Clearance Officer on (240) 276–

1243. 

Comments are invited on: (a) Whether 

the proposed collections of information 

are necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Proposed Project: Strategic Prevention 

Framework State Incentive Grant (SPF 

SIG) Program (OMB No. 0930–0279) 

Revision 

SAMHSA’s Center for Substance 

Abuse Prevention (CSAP) is responsible 

for the evaluation instruments of the 

Strategic Prevention Framework State 

Incentive Grant (SPF SIG) Program. The 

program is a major national initiative 

designed to: (1) Prevent the onset and 

reduce the progression of substance 

abuse, including childhood and 

underage drinking; (2) reduce substance 

abuse related problems in communities; 

and, (3) build prevention capacity and 

infrastructure at the State/territory/Tribe 

and community levels. 

Five steps comprise the SPF: 


jlentini on PROD1PC65 with NOTICES